Developing a new generation of breast cancer clinical gene expression tests

about

An international comparability study on quantification of mRNA gene expression ratios: CCQM-P103.1.MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer.

P2860

Q37000029-7452FCAB-B8B6-4F06-B196-1B9DC47B37A6 Q41545259-543A61EF-FE34-42FA-9F00-43508A2FAE03

P2860

Developing a new generation of breast cancer clinical gene expression tests

Item

http://www.wikidata.org/entity/Q42737349

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Developing a new generation of breast cancer clinical gene expression tests

@en

Developing a new generation of breast cancer clinical gene expression tests

@nl

type

Item

label

Developing a new generation of breast cancer clinical gene expression tests

@en

Developing a new generation of breast cancer clinical gene expression tests

@nl

prefLabel

Developing a new generation of breast cancer clinical gene expression tests

@en

Developing a new generation of breast cancer clinical gene expression tests

@nl

P1476

Developing a new generation of breast cancer clinical gene expression tests

@en

P2093

Torsten O Nielsen

http://www.w3.org/2001/XMLSchema#string

Zuzana Kos

http://www.w3.org/2001/XMLSchema#string

P2860

Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

Gene expression profiling predicts clinical outcome of breast cancer

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Supervised risk predictor of breast cancer based on intrinsic subtypes

Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens

Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.

P2888

bcr3688

P304

103

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1186/BCR3688

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274833243

http://www.w3.org/2001/XMLSchema#string

P6179

1034269038

http://www.w3.org/2001/XMLSchema#string

P698

25928431

http://www.w3.org/2001/XMLSchema#string

P932

4100317

http://www.w3.org/2001/XMLSchema#string

Developing a new generation of breast cancer clinical gene expression tests

about

P2860

P2860

Developing a new generation of breast cancer clinical gene expression tests

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P6179

P698

P932